Talk Bio

Hengrui Pharma and Kailera Therapeutics announced positive topline results from a Phase 2 trial of once-daily oral ribupatide (HRS9531/KAI-9531-T), a GLP-1/GIP dual agonist, in 166 adults with obesity in China. 1 3 Participants achieved mean weight loss of up to 12.1% at 26 weeks (efficacy estimand I) or 11.9% at 50 mg dose (treatment policy estimand II), compared to 2% for placebo, with no plateau observed. 1 2 3 Over 50% on the highest dose lost ≥10% body weight; gastrointestinal side effects were mild to moderate, with vomiting in ≤11.4% and nausea in ≤22.7%. 1 3 4 Hengrui plans to rapidly advance to Phase 3 trial in China; Kailera to initiate global Phase 2 trial in 2026. 1 3 5 This oral version complements injectable ribupatide, in global Phase 3 (KaiNETIC), which showed 23.6% weight loss at 36 weeks. 3 News released February 10, 2026. 2 4 Sources: 1. https://www.biopharmadive.com/news/kailera-hengrui-oral-ribupatide-study-results-china/811718/ 2. https://www.fierc...